EU/3/11/900: Orphan designation for the treatment of ovarian cancer
20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate
Table of contents
Overview
On 27 September 2011, orphan designation (EU/3/11/900) was granted by the European Commission to Nektar Therapeutics UK Ltd, United Kingdom, for 20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate for the treatment of ovarian cancer.
Key facts
Active substance |
20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate
|
Intended use |
Treatment of ovarian cancer
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/11/900
|
Date of designation |
27/09/2011
|
Sponsor |
Nektar Therapeutics UK Ltd
White Rose House 28A York Place Leeds West Yorkshire LS1 2EZ United Kingdom Telephone: +44 113 224 5450 Telefax: +44 113 224 5498 E-mail: cdifonzo@nektar.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: